CME Sessions at EANM’05

EANM’05 – CME Session III

Oncology
October 16, 2005, 14:30 – 16:00
The role of Nuclear Medicine in Gastroenteropancreatic (GEP) tumours

Moderator: F. Pons (Barcelona)
CoModerator: W. Langsteger (Linz)


Speakers:
extended
abstract
E. Bombardieri (Milan):
Receptor scintigraphy for imaging GEP tumours
W. Langsteger (Linz):
Current status of PET in GEP tumours
I. Virgolini (Innsbruck):
Radionuclide therapy of GEP tumours


Educational objectives:

Upon completion of this course the attendee will be able to:

  1. Raise awareness of receptor scintigraphy in the localization, staging and follow up of GEP tumours
  2. Recognise the main radiopharmaceuticals used for receptor scintigraphy and radionuclide therapy in GEP tumours
  3. Appreciate the value of PET in the evaluation of patients with GEP tumours
  4. Estimate which patients may benefit from receptor-targeted radiopeptide therapy
  5. Be aware of the new perspectives of peptide receptor radioligands for the diagnosis and therapy of GEP tumours


Summary:

This course is designed for physicians involved or interested in the diagnostic and therapeutic field of neuroendocrine tumours. We will begin with an overview of the main characteristics of receptor scintigraphy, emphasizing its role for localizing and staging GEP tumours and its clinical usefulness in the follow-up of these patients. Radiotracers used for imaging GEP tumours will be presented, including labelled somatostatin analogues and other radiolabelled peptides for tumour targeting, mainly focusing on somatostatin receptor scintigraphy. PET is not routinely used for imaging GEP tumours but a lecture on this topic will present the current status and show the potential usefulness of PET in the evaluation of these patients. The final lecture will be dedicated to therapeutic aspects. An overview of radiolabelled somatostatin analogs and other peptide receptor imaging agents with therapeutic potential will be given. Current applications and perspectives of peptide receptor radioligands for therapy will be explained. It is expected that the participant has some experience in the application of nuclear medicine procedures for diagnosis and therapy in oncology and endocrinology.


Key Words:

  1. Gastroenteropancreatic tumours
  2. somatostatin
  3. peptide receptor radioligands
  4. receptor scintigraphy
  5. PET
  6. radionuclide therapy
Back to top